|
Enaleni - Successful Fundraising For The Acquisition Of Cipla Medpro
Warning: The listing of ordinary shares in the company is on ALTx. Investors
are advised of the risks of investing in a company listed on ALTx. Investors are
advised that the JSE does not guarantee the viability or the success of a
company listed on ALTx. In terms of the Listings Requirements, the company is
obliged to appoint and retain a Designated Adviser, which is required to, inter
alia, attend all board meetings held by the company to ensure that all the
Listings Requirements and applicable regulations are complied with, approve the
Financial Director of the company and guide the company in a competent,
professional and impartial manner. If the company fails to retain a Designated
Adviser, it must make arrangements to appoint a new Designated Adviser within 10
business days, failing which the company faces suspension of trading of its
securities. If a Designated Adviser is not appointed within 30 days of its
suspension, the company faces the termination of its listing without the
prospect of an appropriate offer to minority shareholders.
Enaleni Pharmaceuticals Limited
(Incorporated in the Republic of South Africa)
(Registration number 2002/018027/06)
(JSE code: ENL ISIN: ZAE000067740)
("Enaleni" or "the company")
SUCCESSFUL FUNDRAISING FOR THE ACQUISITION OF CIPLA MEDPRO HOLDINGS (PTY)
LIMITED ("Cipla Medpro")
Introduction
The directors of Enaleni are pleased to advise shareholders that, further to the
announcements dated 26 September 2005, 21 October 2005 and 31 October 2005,
where it was stated that R990 million (excluding expenses) was to be raised
through a combination of equity and debt funding, Enaleni was more than twice
oversubscribed for the required equity funding of the acquisition of 100% of the
ordinary shares in Cipla Medpro ("the Cipla Medpro transaction"). The requisite
commitments for the debt funding have also been obtained.
Circular to shareholders
A circular to Enaleni shareholders containing details of the Cipla Medpro
transaction and incorporating a notice of general meeting of shareholders will,
subject to approval by the JSE, be mailed to shareholders on or about Monday, 28
November 2005. Shareholders will be notified once the Cipla Medpro transaction
becomes unconditional.
Independent Designated Adviser, Investment Bank and Joint Corporate Adviser and
Arranger
Nedbank Capital
Designated Adviser and Joint Corporate Adviser and Arranger
Exchange Sponsors
Independent Auditors and Reporting Accountants
KPMG Inc.
Independent Auditors and Reporting Accountants to Cipla Medpro
Moores Rowland
Attorneys
Deneys Reitz Inc
Johannesburg
16 November 2005
Date: 16/11/2005 05:59:04 PM Produced by the JSE SENS Department
| Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information. | |||||||||||||
| Other Profile Group sites: FundsData Online (unit trust data) | Profile Group corporate site | |||||||||||||
| [ Terms of Use | Privacy Policy | PAIA manual | FAQs/Help | Site Map | © Copyright Reserved 2026 ] | |||||||||||||
|
|||||||||||||
